Scaling AI governance from pilot to production in healthcare requires governance infrastructure built during the pilot phase — not assembled after scaling decisions are made. AI in healthcare is delivering only 15% of its $200 to $300 billion potential, with only 25% of initiatives achieving expected ROI and 70% of organizations reporting at least one failed AI pilot due to weak endpoints, workflow misalignment, or data gaps. Organizations with mature AI governance are 2.3 times more likely to scale AI successfully, health systems with an AI Governance Council are twice as likely to achieve ROI within 12 months, and pilots with a named owner and tested kill-switch are twice as likely to scale system-wide within a year.
Key Points:
Governance infrastructure established during the pilot phase — including success metrics, go/no-go KPIs, cross-functional committee formation, named accountability owners, workflow integration standards, and compliance documentation — creates the foundation that scaling builds on, while governance assembled after scaling decisions are made cannot retroactively address the design gaps that pilot-purgatory and production failures reflect.
Required pre-pilot structures include defined success metrics and go/no-go KPIs against documented baselines, a cross-functional governance committee including data scientists, IT security, clinical subject matter experts, and product leaders with a C-suite or VP-level AI lead, a named clinical or business owner accountable for outcomes and adoption, and standardized scoring rubrics for evaluating the pilot against strategic alignment, feasibility, risk, and total cost of ownership.
Scalable governance requires standardized policies with automated KPI tracking, centralized compliance reporting in a single platform, automated monitoring that flags issues like model degradation across multiple simultaneous AI projects, a centralized registry of all AI projects reviewed quarterly, and federated AI approaches that address data challenges without requiring massive infrastructure changes.
Production readiness requires seamless workflow integration, compliance with HIPAA and applicable FDA guidelines documented during the pilot, production standards covering uptime, latency, auditability, and security defined during pilot development, risk-tiered approval processes calibrated to patient safety stakes, and a clear go/no-go decision within 90 to 180 days.
Monitoring requires the five-step process of baseline validation, drift surveillance, human review, scheduled recalibration, and governance reporting — with automated drift detection analyzing at least 1,000 recent predictions, bias and fairness evaluations every 30 days, clinician feedback channels for reporting unexpected behavior, and automated circuit breakers that deactivate models when error rates exceed 5%.
Production AI performance degrades without monitoring — a documented mortality prediction model's AUROC dropped 0.29 after a system-wide documentation update, demonstrating that probability estimate drift affecting clinical decisions occurs during normal operational events rather than only during significant system changes.